Tarsus Pharmaceuticals In... (TARS)
Tarsus Pharmaceuticals Statistics
Share Statistics
Tarsus Pharmaceuticals has 41.61M shares outstanding. The number of shares has increased by 10.13% in one year.
| Shares Outstanding | 41.61M |
| Shares Change (YoY) | 10.13% |
| Shares Change (QoQ) | 8.84% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 35.81M |
| Failed to Deliver (FTD) Shares | 16.08K |
| FTD / Avg. Volume | 2.4% |
Short Selling Information
The latest short interest is 7.02M, so 18.36% of the outstanding shares have been sold short.
| Short Interest | 7.02M |
| Short % of Shares Out | 18.36% |
| Short % of Float | 21.55% |
| Short Ratio (days to cover) | 9.42 |
Valuation Ratios
The PE ratio is undefined and the forward PE ratio is -26.42. Tarsus Pharmaceuticals's PEG ratio is undefined.
| PE Ratio | undefined |
| Forward PE | -26.42 |
| PS Ratio | 11.38 |
| Forward PS | 2.2 |
| PB Ratio | 9.27 |
| P/FCF Ratio | undefined |
| PEG Ratio | undefined |
Enterprise Valuation
Tarsus Pharmaceuticals Inc. has an Enterprise Value (EV) of 401.8M.
| EV / Earnings | -3.48 |
| EV / Sales | 2.2 |
| EV / EBITDA | -3.76 |
| EV / EBIT | -3.33 |
| EV / FCF | -4.75 |
Financial Position
The company has a current ratio of 4.42, with a Debt / Equity ratio of undefined.
| Current Ratio | 4.42 |
| Quick Ratio | 4.39 |
| Debt / Equity | undefined |
| Total Debt / Capitalization | 24.4 |
| Cash Flow / Debt | -1.15 |
| Interest Coverage | undefined |
Financial Efficiency
Return on equity (ROE) is -0.51% and return on capital (ROIC) is -40.6%.
| Return on Equity (ROE) | -0.51% |
| Return on Assets (ROA) | -0.31% |
| Return on Capital (ROIC) | -40.6% |
| Revenue Per Employee | $566,417.96 |
| Profits Per Employee | $-357,752.32 |
| Employee Count | 323 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 4.9 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 43.65% in the last 52 weeks. The beta is 1.06, so Tarsus Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.06 |
| 52-Week Price Change | 43.65% |
| 50-Day Moving Average | 49.02 |
| 200-Day Moving Average | 40.03 |
| Relative Strength Index (RSI) | 57.9 |
| Average Volume (20 Days) | 670.82K |
Income Statement
In the last 12 months, Tarsus Pharmaceuticals had revenue of 182.95M and earned -115.55M in profits. Earnings per share was -3.07.
| Revenue | 182.95M |
| Gross Profit | 170.13M |
| Operating Income | -120.57M |
| Net Income | -115.55M |
| EBITDA | -106.88M |
| EBIT | -120.57M |
| Earnings Per Share (EPS) | -3.07 |
Balance Sheet
The company has 94.82M in cash and 72.45M in debt, giving a net cash position of 22.37M.
| Cash & Cash Equivalents | 94.82M |
| Total Debt | 72.45M |
| Net Cash | 22.37M |
| Retained Earnings | -360.21M |
| Total Assets | 376.99M |
| Working Capital | 276.09M |
Cash Flow
In the last 12 months, operating cash flow was -83.03M and capital expenditures -1.57M, giving a free cash flow of -84.59M.
| Operating Cash Flow | -83.03M |
| Capital Expenditures | -1.57M |
| Free Cash Flow | -84.59M |
| FCF Per Share | -2.25 |
Margins
Gross margin is 92.99%, with operating and profit margins of -65.9% and -63.16%.
| Gross Margin | 92.99% |
| Operating Margin | -65.9% |
| Pretax Margin | -63.16% |
| Profit Margin | -63.16% |
| EBITDA Margin | -58.42% |
| EBIT Margin | -65.9% |
| FCF Margin | -46.24% |
Dividends & Yields
TARS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -5.96% |
| FCF Yield | -3.95% |
Analyst Forecast
The average price target for TARS is $66, which is 28.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $66 |
| Price Target Difference | 28.2% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 7.32 |
| Piotroski F-Score | 3 |